<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
------------------
Date of Report (Date of earliest event reported): November 1, 1999
EPIX Medical, Inc.
(Exact name of registrant as specified in its charter)
Delaware 000-21863 04-3030815
------------- ------------- --------------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification No.)
incorporation)
71 ROGERS STREET
CAMBRIDGE, MASSACHUSETTS 02142
---------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (617) 250-6000.
---------------------------------------------------
<PAGE>
ITEM 5. OTHER EVENTS.
On November 2, 1999, the Registrant publicly announced that the
Registrant promoted Stephen C. Knight, M.D. to President and the newly
created position of Chief Operating Officer from his previous position as the
Registrant's Senior Vice President and Chief Financial Officer. The
information contained in the press release containing the announcement is
incorporated herein by reference and filed as Exhibit 99.1 hereto.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits.
99.1 The Registrant's Press Release dated November 2, 1999.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
EPIX MEDICAL, INC.
(Registrant)
Date: November 2, 1999 /s/ Michael D. Webb
------------------------
Michael D. Webb
Chief Executive Officer
<PAGE>
EXHIBIT 99.1
------------
AT EPIX MEDICAL AT FEINSTEIN KEAN PARTNERS
- --------------- --------------------------
Michael Webb -- Chief Executive Fran DeVellis -- Manager (617) 577-8110
Officer E-mail: [email protected]
Sydney Barrett -- Investor Relations
(617) 250-6012
EPIX MEDICAL PROMOTES STEPHEN C. KNIGHT, M.D. TO PRESIDENT AND COO
-- COMPANY CONTINUES TO PREPARE FOR COMMERCIALIZATION OF PRODUCTS --
CAMBRIDGE, MA, NOVEMBER 2, 1999 -- EPIX Medical, Inc. (Nasdaq: EPIX), a
developer of specialty pharmaceuticals for magnetic resonance imaging (MRI),
today announced the promotion of Stephen C. Knight, M.D., to President and
the newly created position of Chief Operating Officer, from his current role
as Chief Financial Officer. Michael D. Webb will continue in his role as
Chief Executive Officer and will assume the additional responsibilities of
finance and corporate administration, effective November 1. The promotion
reflects the Company's ongoing preparations for the anticipated transition
from product development to commercialization.
"Over the last three years, EPIX has systematically put into place all of the
elements needed for a successful business. We have advanced our lead product,
AngioMARK-TM-, into Phase III trials; initiated Phase II trials for
additional AngioMark indications; built a corporate infrastructure with
approximately 85 employees; and established strategic collaborations with
leading MRI equipment manufactures. Steve has contributed significantly to
these accomplishments. We believe that as President and COO, he can lead the
Company's day-to-day operations as we move towards full-scale
commercialization," said Michael D. Webb, Chief Executive Officer of EPIX.
Dr. Knight joined the Company in July 1996 as VP of Strategic Planning and
Business Development. In that role, he spearheaded the Company's successful
public offering on the Nasdaq exchange and helped establish multiple
corporate partnerships with medical equipment companies such as GE, Philips
and Siemens. From April 1991 to June 1996, Dr. Knight was a senior consultant
with Arthur D. Little, specializing in biotechnology, pharmaceuticals and
valuation. Dr. Knight was also a consultant at APM, Inc., a consulting
company. Prior to 1990, Dr. Knight performed research at AT&T Bell
Laboratories, the National Institute of Neurological and Communicative
Diseases and Stroke, and Yale University. He serves on the board of directors
of Pharmos, Inc. Dr. Knight holds an M.D. degree from the Yale University
School of Medicine and an MBA degree from the Yale School of Organization and
Management.
-more-
<PAGE>
EPIX Medical, based in Cambridge, MA, is developing targeted contrast agents
to improve the capability of MRI as a diagnostic tool for a variety of
diseases. The Company's principal product under development, AngioMARK, is an
investigational new drug. In addition to the ongoing Phase III clinical
trials for aortoiliac occlusive disease, AngioMARK is currently in Phase II
feasibility trials for coronary disease and breast cancer.
To receive EPIX Medical's latest news and other corporate developments please
visit the EPIX Medical Web site at www.epixmed.com.
THIS NEWS RELEASE CONTAINS FORWARD-LOOKING STATEMENTS BASED ON CURRENT
EXPECTATIONS OF THE COMPANY'S MANAGEMENT. SUCH STATEMENTS ARE SUBJECT TO
RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER FROM THOSE
PROJECTED, INCLUDING RISKS AND UNCERTAINTIES RELATED TO THE CONDUCT OF, AND
RESULTS OBTAINED FROM, CLINICAL TRIALS; THE TIMING AND SCOPE OF APPROVALS
RECEIVED FROM REGULATORY AGENCIES; THE DEPENDENCE ON STRATEGIC ALLIANCES;
COMPETITION; AND TECHNOLOGICAL CHANGE.
###
